Gene Therapy For Retinal Diseases Market
完整報告名稱與涵蓋範圍
Gene Therapy For Retinal Diseases Market Size, Share & Trends Analysis Report By Indication (Choroideremia (CHM), Leber Congenital Amaurosis, Leber’s Hereditary Optic Neuropathy, X-Linked Retinitis Pigmentosa, and Other Indications), Region And Segment Forecasts, 2023-2031.
報告摘要
Industry analysis indicates the Gene Therapy For Retinal Diseases Market globally will expand at a 8.0% CAGR during 2023–2031.
The Gene Therapy For Retinal Diseases sector involves dynamics.
The market's upward path is supported by escalating healthcare spending, technological evolution, and the escalating focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region forecasted to deliver the strongest growth trajectory through the forecast period, supported by demographic shifts and policy support.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene Therapy for Retinal Diseases Market Snapshot
Chapter 4. Global Gene Therapy for Retinal Diseases Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Epidemiology: Incidence Prevalence Analysis 2019
4.6.1. Choroideremia (CHM)
4.6.2. Leber congenital amaurosis
4.6.3. Leber's hereditary optic neuropathy
4.6.4. Retinitis pigmentosa
4.6.5. X-linked retinitis pigmentosa
4.6.6. X-linked retinoschisis
4.6.7. Usher syndrome type 1B
4.6.8. Stargardt disease
4.6.9. Achromatopsia
4.6.10. Neovascular/age-related macular degeneration
4.7. Clinical Trial/Pipeline Analysis
4.8. Industry Analysis – Porter's Five Forces Analysis
4.9. Technology Advancement in Gene Therapy for Retinal Diseases Market
Chapter 5. Market Segmentation 1: Indication Estimates & Trend Analysis
5.1. Indication Type & Market Share, 2020 & 2030
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Indication:
5.2.1. Choroideremia (CHM)
5.2.2. Leber congenital amaurosis
5.2.3. Leber's hereditary optic neuropathy
5.2.4. Retinitis pigmentosa
5.2.5. X-linked retinitis pigmentosa
5.2.6. X-linked retinoschisis
5.2.7. Usher syndrome type 1B
5.2.8. Stargardt disease
5.2.9. Achromatopsia
5.2.10. Neovascular/age-related macular degeneration
5.2.11. Other Indication
Chapter 6. Gene Therapy for Retinal Diseases Market Segmentation 3: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by Indication, 2020-2030
6.1.2. North America Gene Therapy for Retinal Diseases Market revenue (US$ Million) estimates and forecasts by country, 2020-2030
6.1.2.1. U.S.
6.1.2.2. Canada
6.2. Europe
6.2.1. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030
6.2.2. Europe Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030
6.2.2.1. Germany
6.2.2.2. Poland
6.2.2.3. France
6.2.2.4. Italy
6.2.2.5. Spain
6.2.2.6. UK
6.2.2.7. Rest of Europe
6.3. Asia Pacific
6.3.1. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, 2020-2030
6.3.2. Asia Pacific Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, 2020-2030
6.3.2.1. China
6.3.2.2. India
6.3.2.3. Japan
6.3.2.4. Australia
6.3.2.5. Rest of Asia Pacific
6.4. Latin America
6.4.1. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million)
6.4.2. Latin America Gene Therapy for Retinal Diseases Market revenue (US$ Million) by country, (US$ Million) 2020-2030
6.4.2.1. Brazil
6.4.2.2. Rest of Latin America
6.5. MEA
6.5.1. MEA revenue Gene Therapy for Retinal Diseases Market revenue (US$ Million) by Indication, (US$ Million) 2020-2030
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Applied Genetic Technologies Corporation
7.2.2. Adverum Biotechnologies
7.2.3. ProQR Therapeutics
7.2.4. MeiraGTx Limited.
7.2.5. Oxford BioMedica
7.2.6. Horama S.A.
7.2.7. Gensight Biologics
7.2.8. Regenxbio Inc.
7.2.9. Spark Therapeutics, Inc.
7.2.10. Genzyme (Sanofi)
7.2.11. Novartis Pharmaceuticals
7.2.12. Nightstar Therapeutics (Biogen)
7.2.13. Hemera Biosciences
7.2.14. ViGeneron GmbH
7.2.15. Allergan
7.2.16. Eyevensys
7.2.17. Clearside Biomedical
7.2.18. IVERIC bio, Inc.
7.2.19. Other Prominent Players
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們